- Home
- ROOT vs AGIO Comparison
ROOT vs AGIO Comparison
Compare ROOT & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- AGIO
- Stock Information
- Founded
- ROOT 2015
- AGIO 2007
- Country
- ROOT United States
- AGIO United States
- Employees
- ROOT N/A
- AGIO N/A
- Industry
- ROOT Property-Casualty Insurers
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- ROOT Finance
- AGIO Health Care
- Exchange
- ROOT Nasdaq
- AGIO Nasdaq
- Market Cap
- ROOT 2.3B
- AGIO 2.1B
- IPO Year
- ROOT 2020
- AGIO 2013
- Fundamental
- Price
- ROOT $95.81
- AGIO $37.60
- Analyst Decision
- ROOT Buy
- AGIO Buy
- Analyst Count
- ROOT 6
- AGIO 6
- Target Price
- ROOT $130.60
- AGIO $57.00
- AVG Volume (30 Days)
- ROOT 438.0K
- AGIO 787.6K
- Earning Date
- ROOT 10-29-2025
- AGIO 10-30-2025
- Dividend Yield
- ROOT N/A
- AGIO N/A
- EPS Growth
- ROOT N/A
- AGIO N/A
- EPS
- ROOT 4.73
- AGIO 11.13
- Revenue
- ROOT $1,364,700,000.00
- AGIO $40,875,000.00
- Revenue This Year
- ROOT $27.41
- AGIO $23.66
- Revenue Next Year
- ROOT $9.74
- AGIO $143.65
- P/E Ratio
- ROOT $20.90
- AGIO $3.26
- Revenue Growth
- ROOT 59.76
- AGIO 30.57
- 52 Week Low
- ROOT $36.87
- AGIO $23.42
- 52 Week High
- ROOT $181.14
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- ROOT 47.82
- AGIO 52.27
- Support Level
- ROOT $94.78
- AGIO $35.72
- Resistance Level
- ROOT $102.47
- AGIO $37.18
- Average True Range (ATR)
- ROOT 4.57
- AGIO 1.54
- MACD
- ROOT 1.65
- AGIO -0.06
- Stochastic Oscillator
- ROOT 57.16
- AGIO 58.27
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.